Haley Gittleman
0000-0002-6976-8777
Publication & Citation Trends
Publications
0 total
RE: is it time to reconsider the role of upfront cytoreductive nephrectomy in metastatic renal cell carcinoma?
Cited by 0
Semantic Scholar
US Food and Drug Administration Approval Summary: Elacestrant for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer
Cited by 25
Semantic Scholar
Cytoreductive nephrectomy in the era of immune checkpoint inhibitors: a U.S. FDA pooled analysis. OA
Cited by 7
Semantic Scholar
A Pooled Analysis of Treatment-Free Survival in Advanced Renal Cell Carcinoma.
Cited by 2
Semantic Scholar
FDA pooled analysis of overall survival according to depth of response as a continuous variable in frontline advanced immuno-oncology renal cell carcinoma trials.
Cited by 0
Semantic Scholar
FDA Approval Summary: Mirvetuximab soravtansine-gynx for FRα-positive, Platinum-Resistant Ovarian Cancer. OA
Cited by 74
Semantic Scholar
FDA analysis of treatment-free survival in frontline advanced immuno-oncology–VEGF TKI renal cell carcinoma trials.
Cited by 2
Semantic Scholar
A U.S. Food and Drug Administration-pooled Analysis of Frontline Combination Treatment Survival Benefits by Risk Groups in Metastatic Renal Cell Carcinoma.
Cited by 16
Semantic Scholar
Research Topics
Glioma Diagnosis and Treatment
(44)
Renal cell carcinoma treatment
(28)
Brain Metastases and Treatment
(26)
Meningioma and schwannoma management
(12)
Cancer Genomics and Diagnostics
(12)
Affiliations
Boston University
Cleveland Clinic
United States Food and Drug Administration
Barrow Neurological Institute
Center for Drug Evaluation and Research